Text Size

Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: Results from a pharmacodynamics analysis

Hamacher T., Airaksinen J., Saarela V., Liinamaa M.J., Richter U., Ropo A.


  • 2008
  • Acta Ophthalmologica
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Augenzentrum Dr Hamacher Praxis, Maximilianstrasse 2B D-82319, Starnberg, Germany; Department of Ophthalmology, Oulu University Hospital, Oulu, Finland; Private Practice, Regensburg, Germany; Department of Clinical Research, Santen Oy, Helsinki, Finland

Related Publications

Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF


Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.


Cost-utility analysis of latanoprost unidose cationic emulsion preservative-free versus latanoprost unidose in the treatment of open-angle glaucoma and ocular hypertension patients in Spain

Canut MI, García-Feijoo J, Larrosa-Poves JM, López-López F, Pazos M, Espinoza-Cámac N, Oyagüez I, Del Rio T, Rodríguez M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022